Published in
BioMed Central, Arthritis Research and Therapy, 1(20), 2018
DOI: 10.1186/s13075-018-1773-y
Links
Tools
Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study
Journal article published in 2018 by
L. C. Coates 
,
D. D. Gladman,
Peter Nash ,
O. FitzGerald,
A. Kavanaugh,
T. K. Kvien,
L. Gossec,
V. Strand,
L. Rasouliyan,
L. Pricop,
K. Ding,
S. M. Jugl,
2. Study Group Future,
C. Gaillez,
Future study Group
,
D. D. Gladman,
Peter Nash ,
O. FitzGerald,
A. Kavanaugh,
T. K. Kvien,
L. Gossec,
V. Strand,
L. Rasouliyan,
L. Pricop,
K. Ding,
S. M. Jugl,
2. Study Group Future,
C. Gaillez,
Future study Group
This paper is made freely available by the publisher.
Full text: Download
Data provided by 